newsfilter
← Latest News
Business Wire·

TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer

  • TriSalus Life Sciences will host a virtual KOL event on June 24, 2026, at 8:00 AM ET to present real-world outcomes data for its Pressure-Enabled Drug Delivery (PEDD) technology.
  • A newly published study demonstrates a 48% improvement in drug delivery to target tumors with PEDD compared to conventional embolization approaches.
  • Clinical results indicate that sicker patients experienced fewer adverse events & a 61% reduction in hospital readmissions.
  • The study findings apply to the estimated 900,000 patients diagnosed annually worldwide with primary liver tumors or liver metastases.
  • Dr. Alexander S. Misono, Chief of Interventional Radiology at Hoag Hospital, will join TriSalus management to discuss treatment strategies & share case examples using the TriNav Infusion System.
  • The TriNav Infusion System is one of three FDA-cleared devices in the TriSalus platform utilizing the PEDD approach to modulate pressure & flow for targeted delivery.
  • TriSalus also develops nelitolimod, an investigational immunotherapeutic candidate, for use with its PEDD technology in Phase 1 clinical trials.
  • The company is in final stages of data completion for several Phase 1 trials & plans to explore partnership opportunities for further development.